TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from PureTech Health ( (GB:PRTC) ).
PureTech Health has announced promising new data from its Phase 2b ELEVATE IPF trial for deupirfenidone (LYT-100), a potential new standard of care for idiopathic pulmonary fibrosis (IPF). The data, presented at the 2025 European Respiratory Society Congress, showed that patients switching from placebo or pirfenidone to deupirfenidone experienced stabilization of lung function with favorable tolerability, reinforcing the drug’s potential to address unmet needs in IPF treatment. The company is engaging with regulators to finalize the Phase 3 trial design, with updates expected in Q4 2025.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score reflects a mixed financial performance with strong liquidity but challenges in profitability. Technical indicators suggest bearish momentum, while the valuation appears attractive. The earnings call provided a cautiously optimistic outlook, though management changes and funding uncertainties pose risks.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value through a capital-efficient R&D model. It has developed multiple therapeutic candidates, including three that have received U.S. FDA approval, by identifying and scaling high-conviction assets through dedicated structures backed by external capital.
Average Trading Volume: 728,281
Technical Sentiment Signal: Strong Sell
Current Market Cap: £302.1M
For a thorough assessment of PRTC stock, go to TipRanks’ Stock Analysis page.